Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine vs sufentanil for postoperative gastrointestinal recovery after gynecologic cancer surgery
ChiCTR-IPR-17011658Phase 4Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine in postoperative pain and Postoperative gastrointestinal dysfunction (POGD) (2 arms), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoints: Time to first flatus and Time to first defecation. Started Jun 2017; status: recruiting.
02
Drugs
nalbuphine
03
Conditions
postoperative painPostoperative gastrointestinal dysfunction (POGD)
Beyond the preview
Go deeper on ChiCTR-IPR-17011658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011658.